Silvan Tuerkcan

While recent pullback in Seattle Genetics, Inc’s (NASDAQ: SGEN) shares presents an attractive entry point, there are several pipeline catalysts ahead, according to Oppenheimer. The Analyst Oppenheimer’s Silvan Tuerkcan upgraded the rating on Seattle Genetics to Outperform while raising...

Axovant Sciences Ltd (NASDAQ: AXON) announced Wednesday that it licensed global rights to Oxford BioMedica’s investigational gene therapy for Parkinson’s Disease. As some experts see it, the drug could be a game changer. The Rating Oppenheimer analysts Jay Olson and Silvan Tuerkcan...

Incyte Corporation (NASDAQ: INCY) traded down 5.5 percent Wednesday despite posting 6-percent revenue and 143-percent earnings per share beat Tuesday. But analysts were more receptive to the quarterly report. BMO Capital raised its price target to $166, Barclays reiterated positive outlook and...